Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2014 1
2015 1
2016 2
2017 2
2018 1
2019 2
2020 2
2021 1
2022 3
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML.
Bennett J, Ishikawa C, Agarwal P, Yeung J, Sampson A, Uible E, Vick E, Bolanos LC, Hueneman K, Wunderlich M, Kolt A, Choi K, Volk A, Greis KD, Rosenbaum J, Hoyt SB, Thomas CJ, Starczynowski DT. Bennett J, et al. Among authors: bolanos lc. Blood. 2023 Sep 14;142(11):989-1007. doi: 10.1182/blood.2022018718. Blood. 2023. PMID: 37172199 Free PMC article.
U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies.
Smith MA, Choudhary GS, Pellagatti A, Choi K, Bolanos LC, Bhagat TD, Gordon-Mitchell S, Von Ahrens D, Pradhan K, Steeples V, Kim S, Steidl U, Walter M, Fraser IDC, Kulkarni A, Salomonis N, Komurov K, Boultwood J, Verma A, Starczynowski DT. Smith MA, et al. Among authors: bolanos lc. Nat Cell Biol. 2019 May;21(5):640-650. doi: 10.1038/s41556-019-0314-5. Epub 2019 Apr 22. Nat Cell Biol. 2019. PMID: 31011167 Free PMC article.
The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia.
Niederkorn M, Ishikawa C, M Hueneman K, Bartram J, Stepanchick E, R Bennett J, E Culver-Cochran A, Bolanos LC, Uible E, Choi K, Wunderlich M, Perentesis JP, M Chlon T, Filippi MD, Starczynowski DT. Niederkorn M, et al. Among authors: bolanos lc. Leukemia. 2022 Feb;36(2):438-451. doi: 10.1038/s41375-021-01394-z. Epub 2021 Aug 31. Leukemia. 2022. PMID: 34465865 Free PMC article.
ASXL1 mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasms.
Riabov V, Xu Q, Schmitt N, Streuer A, Ge G, Bolanos L, Wunderlich M, Jann JC, Wein A, Altrock E, Demmerle M, Mukherjee S, Ali AM, Rapp F, Nowak V, Weimer N, Obländer J, Palme I, Göl M, Jawhar A, Darwich A, Wuchter P, Weiss C, Raza A, Foulks JM, Starczynowski DT, Yang FC, Metzgeroth G, Steiner L, Jawhar M, Hofmann WK, Nowak D. Riabov V, et al. Among authors: bolanos l. Haematologica. 2024 May 1;109(5):1426-1438. doi: 10.3324/haematol.2023.282921. Haematologica. 2024. PMID: 37916386 Free PMC article.
Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia.
Barreyro L, Sampson AM, Ishikawa C, Hueneman KM, Choi K, Pujato MA, Chutipongtanate S, Wyder M, Haffey WD, O'Brien E, Wunderlich M, Ramesh V, Kolb EM, Meydan C, Neelamraju Y, Bolanos LC, Christie S, Smith MA, Niederkorn M, Muto T, Kesari S, Garrett-Bakelman FE, Bartholdy B, Will B, Weirauch MT, Mulloy JC, Gul Z, Medlin S, Kovall RA, Melnick AM, Perentesis JP, Greis KD, Nurmemmedov E, Seibel WL, Starczynowski DT. Barreyro L, et al. Among authors: bolanos lc. Sci Transl Med. 2022 Mar 9;14(635):eabb7695. doi: 10.1126/scitranslmed.abb7695. Epub 2022 Mar 9. Sci Transl Med. 2022. PMID: 35263148
TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity.
Muto T, Guillamot M, Yeung J, Fang J, Bennett J, Nadorp B, Lasry A, Redondo LZ, Choi K, Gong Y, Walker CS, Hueneman K, Bolanos LC, Barreyro L, Lee LH, Greis KD, Vasyliev N, Khodadadi-Jamayran A, Nudler E, Lujambio A, Lowe SW, Aifantis I, Starczynowski DT. Muto T, et al. Among authors: bolanos lc. Cell Stem Cell. 2022 Feb 3;29(2):298-314.e9. doi: 10.1016/j.stem.2021.12.007. Epub 2022 Jan 18. Cell Stem Cell. 2022. PMID: 35045331 Free PMC article.
Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression.
Matsui S, Ri C, Bolanos LC, Choi K, Shibamiya A, Ishii A, Takaishi K, Oshima-Hasegawa N, Tsukamoto S, Takeda Y, Mimura N, Yoshimi A, Yokote K, Starczynowski DT, Sakaida E, Muto T. Matsui S, et al. Among authors: bolanos lc. Leukemia. 2024 May;38(5):1032-1045. doi: 10.1038/s41375-024-02245-3. Epub 2024 Apr 12. Leukemia. 2024. PMID: 38609495 Free PMC article.
Differential IRAK signaling in hematologic malignancies.
Rhyasen GW, Bolanos L, Starczynowski DT. Rhyasen GW, et al. Among authors: bolanos l. Exp Hematol. 2013 Dec;41(12):1005-7. doi: 10.1016/j.exphem.2013.09.008. Epub 2013 Sep 29. Exp Hematol. 2013. PMID: 24084080 Free PMC article. No abstract available.
Targeting AML-associated FLT3 mutations with a type I kinase inhibitor.
Jones LM, Melgar K, Bolanos L, Hueneman K, Walker MM, Jiang JK, Wilson KM, Zhang X, Shen J, Jiang F, Sutter P, Wang A, Xu X, Tawa GJ, Hoyt SB, Wunderlich M, O'Brien E, Perentesis JP, Starczynowski DT, Thomas CJ. Jones LM, et al. Among authors: bolanos l. J Clin Invest. 2020 Apr 1;130(4):2017-2023. doi: 10.1172/JCI127907. J Clin Invest. 2020. PMID: 32149729 Free PMC article.
Overcoming adaptive therapy resistance in AML by targeting immune response pathways.
Melgar K, Walker MM, Jones LM, Bolanos LC, Hueneman K, Wunderlich M, Jiang JK, Wilson KM, Zhang X, Sutter P, Wang A, Xu X, Choi K, Tawa G, Lorimer D, Abendroth J, O'Brien E, Hoyt SB, Berman E, Famulare CA, Mulloy JC, Levine RL, Perentesis JP, Thomas CJ, Starczynowski DT. Melgar K, et al. Among authors: bolanos lc. Sci Transl Med. 2019 Sep 4;11(508):eaaw8828. doi: 10.1126/scitranslmed.aaw8828. Sci Transl Med. 2019. PMID: 31484791 Free PMC article.
19 results